Abstract
Despite the high efficiency of the use of 18F-FDG PET in the diagnosis, staging, monitoring and prognosis of treatment of lymphomas, the use of this method in our country is limited due to the high cost and the insufficient number of PET-centers. In this regard, it seems relevant to conduct research aimed at using known and developing original radiopharmaceuticals for lymphoma imaging with single-photon emission computed tomography (SPECT). In this review, the main radiopharmaceuticals (67Ga-citrate, 201Tl, 199Tl, 99mTc-methoxy-isobutyl-isonitrile, 99mTc-tetrofosmin, 111In-octreotide), which are possible for SPECT lymphoma imaging are shown. Also mechanisms of their action, the possibility of their using for various morphological variants of lymphomas and localizations of the lesion are described. In addition, the results of the use of an innovative radiopharmaceutical based on glucose - 99mTc-1-thio-D-glucose, which is promising for diagnostics, staging and monitoring of lymphoproliferative diseases, are presented.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
